Cargando…
Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
Alpelisib, a phosphatidylinositol-3-kinase (PI3K) inhibitor, is a new drug approved for metastatic breast cancer. Hyperglycemia is a known side effect of this medication, however diabetic ketoacidosis is rarely described. We are presenting a 64-year-old female with a known case of Type 2 diabetes me...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663995/ https://www.ncbi.nlm.nih.gov/pubmed/34909343 http://dx.doi.org/10.7759/cureus.19441 |